PPD Strengthens Oncology Expertise for Drug Development

Pharmaceutical Product Development (PPD) has appointed Panteli Theocharous vice president of global product development in the hematology/oncology therapeutic area.

“Panteli brings extensive expertise in hematology and oncology and biopharmaceutical R&D to PPD’s global product development team,” said Rob Dow, senior vice president of medical affairs, PPD. “Panteli is a recognized thought leader in oncology, and throughout his career he has worked on marketing authorization applications, lifecycle management and pricing and reimbursement negotiations for more than 20 hematology and oncology molecules.”

Hematology and oncology form one of PPD’s leading therapeutic areas, with more than 400 studies with clinical components conducted in this area in the past five years.

Mr. Theocharous most recently served as vice president and head of clinical and medical affairs at Cell Therapeutics, Life Sciences in London. Previously, he was with Johnson & Johnson, where he held leadership positions in global medical affairs, clinical development and regulatory affairs for the company’s hematology/oncology research and development programs.